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Background: The aim is to evaluate periodontal alteration and biochemical markers associated with bone turnover 
in chronic oral with dicoumarins anticoagulant treatment patients.
Material and Methods: 80 patients treated with oral anticoagulants were divided into 2 cohort: Group A (n=36) 6 
month to 1 year with anticoagulant treatment and Group B (n=44) > 2 years with anticoagulant treatment. Clini-
cal evaluation included: Clinical attachment level (CAL), plaque index (PI) and gingival index (GI). Analytically 
biochemical parameters of bone remodeling (calcium and phosphorus), formation (total acid phosphatase, alkaline 
phosphatase and osteocalcin) and resorption (tartrate-resistant acid phosphatase and beta-crosslaps) were evalu-
ated. 
Results: High values of PI (67-100%) especially in men and in Group B were observed. Men with anticoagulation 
treatment length showed an increased GI (49.167 vs 78.083) while Group B women showed a decreased GI in 
comparison with Group A (59.389 vs 42.120). Women presented a greater average CAL than men as well as Group 
B vs Group A but without statistical significance.
All biochemical markers were decreased respect to values of general population.
Osteocalcin in GroupB women showed a statistically significant outcome vs GroupA (p=0.004). Acid phosphatase 
(total and tartrate-resistant) has a slight increase in Group B women versus Group A, and Beta-crosslap showed 
lower values in Group A men than Group B and slightly lower in Group A women versus Group B, without 
statistical significance.
Conclusions: Patients showed a slight to moderate degree of periodontal affectation, especially gingivitis related 
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to bacterial plaque. Periodontal disorders tended to be more severe in Group B. While bone remodeling showed an 
overall decrease with greater affectation of bone neoformation phenomena, bone destruction tended to recover and 
normalize in time.
Key words: Periodontal disease, dicoumarin, biochemical markers, bone remodeling.
Introduction 
Oral anticoagulant treatment (OAT) with dicoumarins is 
an increasingly common practice in general population 
due to their efficacy and safety (13.19/1000 inhabitants 
in Spanish population are treated with dicoumarins) (1). 
Diverse health care agents are involved in the manage-
ment of oral anticoagulated patients: staff hematologist, 
primary attention doctor, nursing…  
Bleeding and osteoporosis are some of the adverse ef-
fects of these drugs (2). The latter has been exhaus-
tively studied in relation to other anticoagulants such 
as heparins (3). However, the role of coumarins and 
their mechanism of interference through deactivating 
proteins such as GLA proteins and osteocalcin are less 
well known (4). The drug effect on dental treatments 
and on alveolar bone, and their possible repercussions 
for the onset or evolution of periodontitis, particularly 
on bone destruction, has been mentioned in several pa-
pers (5-7).  
Periodontitis is one of the most frequent oral diseases. It 
is an inflammatory and irreversible disease, mediated by 
bacterial biofilm, than affects tooth-supporting tissues, 
inducing an alveolar bone loss, and the progressive de-
velopment of clinical attachment loss. It manifests clini-
cally as the presence of gingival inflammation, bleeding 
(either spontaneous bleeding or as a result of periodon-
tal probing, tooth brushing, etc.) and the appearance of 
periodontal pockets. Its severity is assessed by means of 
the Gingival Index (GI) and Clinical Attachment Level 
(CAL).
Given the high prevalence of periodontal disease in the 
general population, its risk factors (some coinciding 
with the same pathologies that require treatment by oral 
anticoagulants), possible repercussions for the onset 
or evolution of other systemic alterations (diabetes, 
atherosclerosis,…) (8-10), and the growing strata of 
the population receiving anticoagulant treatment, it is 
important to establish the repercussions of dicoumarins 
for the onset, perpetuation and aggravation of 
periodontitis.  
The objective of this study is to evaluate periodontal 
alteration and biochemical markers related to bone 
turnover in patients with chronic oral anticoagulant 
treatment, recording clinical periodontal parameters 
(plaque index -PI-, GI and CAL), biochemical markers 
of bone remodeling (serum ionized calcium and serum 
phosphorus), bone formation markers (total serum acid 
phosphatase, serum bone alkaline phosphatase, serum 
osteocalcin [Bone Gla-protein]) and bone resorption pa-
rameters (tartrate-resistant acid phosphatase and beta-
crosslaps in plasma).
 
Material and Methods 
The study protocol was approved by the Faculty of 
Dentistry Ethics Committee of Granada University and 
followed criteria established in Helsinki Declaration 
for clinical trials. All participants gave their informed 
consent.
-Patients
Patients receiving oral anticoagulants were selected 
from a data base of 3220 anticoagulant patients at the 
Valme Area Hospital (Sevilla, Spain) who fulfilled 
the following inclusion criteria: patients in treatment 
by acenocoumarol; good patient compliance with 
the anticoagulant treatment, defined as least a 80% 
attendance at check-ups (prothrombin time - INR) (11) 
during a required initial period (> 6 months and < 1 year; 
>2 years) were into the therapeutic range established for 
each individual  ± 10% ; whose reason for anticoagulant 
therapy (observe that some patients had more than one 
disease) did not involve risk of periodontal disease or 





Auricular fibrillation 58 72.50%
Ischemic heart disease 21 26.25%
Mechanical cardiac prothesis 11 13.75%
Pulmonary thromboembolism 10 12.50%
Recurrent thromboembolism 2 2.50%
*Some patients had more than one disease.
Table 1. Distribution of participants according to the disease.
periodontal status or bone metabolism, and absence of 
risk factors for periodontal disease or osteoporosis. A 
total of 80 randomly selected patients were included, 
divided into two groups according to treatment length: 
Group A included patients in treatment between six 
months to one year; Group B patients in treatment 
during two years or more. Group A included 36 patients 
(18 men and 18 women, mean age 69.2 + 0.7) and Group 
B 44 patients (24 men and 20 women, mean age 68.8 + 
0.8).
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Given that the total population with oral anticoagulation 
treatment in our area is about 3200 patients it was an 
adequate sample size (12).
After inter-explorer calibration by means of the Cohen 
Kappa test, all patients underwent O’Leary’s Plaque In-
dex (PI) (13), Ainamo and Bay Gingival Index (GI) (14), 
and clinical attachment level (CAL) using a periodontal 
probe (PCPUNC15).
- Biochemical analysis methods 
A blood sample was extracted from all subjects which 
underwent an anticoagulation test by means of the in-
ternational normalized ratio (INR) with a STA© coagu-
lometer and thromboplastin reagents Neoplus© (Roche 
Diagnostics, Basel, Switzerland). Biochemical markers 
of bone remodeling (serum ionized calcium and serum 
phosphorus), markers of bone formation (total serum 
acid phosphatase, serum bone alkaline phosphatase, se-
rum osteocalcin [BGP]) and markers of bone resorption 
(tartrate-resistant acid phosphatase and beta-crosslaps 
in plasma) also were analyzed using a Hitachi Modular 
P800© device and Roche Diagnostic© reagents (Roche 
Diagnostics, Basel, Switzerland); electrophoresis on 
Agarose gel; immunoradiometric assay; kinetic spec-
trophotometry; and enzyme immunoassay. All data 
were perfomed by Balagué Center© laboratories (Bar-
celona, Spain).
- Statistical analysis
Descriptive statistics, variance analysis, and Kruskal-
Wallis non-parametric test were performed using IBM 
SPSS Statistics 23.0 statistical package for Windows 
(IBM Corporation, Armonk, USA). Statistical signifi-
cance was set at p<0.05.
Results
- Periodontal results
Plaque index (PI): All patients showed high values be-
tween 67 and 100%. The oral hygiene was worse in men 
than women, especially in group B patients (Table 2).
Gingival Index (GI): The results showed an increase in 
gingival bleeding in all men patients (Groups A and B) 
related to the treatment anticoagulation length, while in 
Group B women the number of bleeding sites decreased 
in comparison with the others groups (Table 2).
Clinical Attachment Level (CAL): Mean CAL was 
greater in women than men, and both men and women 
showed slightly greater CAL in Group B than Group 
A; neither of them were statistically significant differ-
ent (Table 2).
-Biochemical results
Calcium and phosphorus values were similar in the two 
groups although mean levels were lower compared with 
normal healthy population (Table 3).
Total alkaline phosphatase: In women no statistically 
significant differences were identified (comparing 
Groups A and B or both groups with the estimated 
values for general population). However, in the case of 
male patients, values were significant statistically lower 
than general population in both groups, although higher 
in Group B than Group A (Table 3).
Osteocalcin: Both groups and both genres presented 
lower values than general population. Although men 
showed similar values in both groups, women showed 
a statistically significant improvement in Group B 
(p=0.004) vs. Group A (Table 3).
Acid phosphatase values, both total acid phosphatase 
and tartrate-resistant acid phosphatase, showed statisti-
cally significant reductions in all groups. In men there 
was no relation of anticoagulant treatment length. There 
were lower values in Group A women, however these 
values increased in Group B (Table 3).
Beta Crosslap: In all cases there was a statistically sig-
nificant decrease compared with normal levels in gen-
eral population. Values in men were lower in Group A 
than Group B.  In women there were no statistically 
Group A Group B Total
Index Sex N Mean SD N Mean SD N Mean SD
PI W 18 77.011 26.3092 24 79.530 19.6985 42 78.337 22.7795
PI M 18 87.556 19.9004 20 98.208 6.6853 38 93.643 14.7563
PI Total 36 82.283 23.6039 44 89.718 16.8485 80 86.373 20.3765
GI W 18 59.389 33.8090 20 42.120 37.0992 38 50.300 36.1706
GI M 18 49.167 36.8929 24 78.083 33.5296 42 65.690 37.4806
GI Total 36 54.278 35.2585 44 61.736 39.2124 80 58.380 37.4385
CAL W 18 3.3842 1.19862 20 3.6001 1.69296 38 3.4978 1.46015
CAL M 18 2.9767 .48094 24 3.298 1.00204 42 3.1607 .81528
CAL Total 36 3.1804 .98242 44 3.4357 1.37695 80 3.3208 1.20826
Table 2. Results of periodontal variables of the patients. 
PI, Plaque index; GI, Gingival Index; CAL, Clinical Attachment Level; W, Women; M, Men; N, Number of cases; SD, Standard deviation; Ŧ, 
Statistical significance related to normal population values; *, Statistical significance between groups.
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significant differences between them according to an-
ticoagulation treatment length, although values were 
slightly lower in Group A (Table 3). 
Discussion
As in previous researches, this study chose to evaluate 
serum biochemical markers and bone remodeling pa-
rameters (calcium, phosphorus, alkaline phosphatase, 
beta-crosslaps, total acid phosphatase and tartrate-re-
sistant acid phosphatase) (15). These methods (16) are 
safe, reliable and more feasible than invasive proce-
dures – as bone biopsies are - only requiring a blood 
or urine sample so given the ease of taking samples, 
continuous evaluations of bone metabolism can be con-
ducted easily. 
Results for all these parameters obtained from patients 
taking the anticoagulant warfarin suggest that bone re-
modeling is generally reduced, with increased affecta-
tion of bone neoformation, while bone destruction tends 
to recover and return to a physiological steady state. Pre-
vious studies have evaluated vitamin K and bone min-
eral density in patients administered long term warfarin 
following cerebral ischemic attack, finding that mineral 
bone density is significantly lower between long-term 
warfarin patients than non-treated patients (2,17).
The biochemical action’s mechanism of warfarina and 
coumarins are similar and results from its anti vitamin 
K effect. Their principal difference is settled in their 
different biodisponibility and half life in the organ-
ism, more long and stable for the warfarin. In Spain the 
predominant drugs are coumarins (Sintrom®) and in 
practice the use of warfarin is restricted to patients with 
metallic prosthetic valves, a minority population group, 
and only when  his control with coumarins is very ir-
regular (18,19). 
 It is important to remember that biochemical data and 
clinical disorders are not simultaneous, so that it may 
take a long evolution time for an increase in biochemi-
cal status to translate into clinical pathology. This ac-
tion is also encountered in our study.  
We select two differents cohorts both with enough 
time for develop changes in bone metabolism. The first 
(Group A) has a minimum of six months for that. The 
length of anticoagulant treatment in some pathologies 
(like lung thromboembolism) has usually between 6-12 
months so that we set up the limit of the first group in 
one year. For avoid overlap and can evaluate changes af-
ter a significantly longer period of treatment the second 
group received it for at least 2 years (Group B). Most of 
patients with cardiac diseases meet this condition.
Group A Group B Total
Marker Sex N Mean SD N Mean SD N Mean SD
Ca W 18 9.6930 .23771   20 9.6126 .30719 38 9.6507 .27582
Ca H 18 9.5770 .28131 24 9.6882 .35627 42 9.6406 .32729
Ca Total 36 9.6350 .26333   44 9.6539 .33323 80 9.6454 .30208
P W 18 3.254 .5547 20 2.941 .4535 38 3.089 .5216
P H 18 3.110 .4493 24 3.139 .5429 42 3.126 .4992
P Total 36 3.182 .5028 44 3.049 .5083 80 3.109 .5071
Al-P W 18 43.506 14.2824 20 47.715 17.7023 38 45.419 15.8767
Al-P M 18 46.202Ŧ 12.2830 24 41.018Ŧ 17.6416 42 43.610 Ŧ 15.2104
Al-P Total 36 44.661 13.3720 44 44.543 17.7595 80 44.605 15.5088
BGP W 18 4.3996 2.17371 20 7.7995* 4.22756 38 6.1890 3.78263
BGP M 18 4.6601 2.01391 24 5.2383 2.25413 42 4.9905 2.14847
BGP Total 36 4.5299 2.06941 44 6.4025 3.50415 80 5.5598 3.07566
Total-AP W 18 1.100Ŧ .9431 20 1.922Ŧ 1.1674 38 1.533 Ŧ 1.1322
Total-AP M 18 2.395Ŧ .5997 24 1.970Ŧ .8043 42 2.152 Ŧ .7465
Total-AP Total 36 1.747 1.0188 44 1.948 .9741 80 1.858 .9932
TR-AP W 18 .980Ŧ .7501 20 1.590Ŧ 1.0168 38 1.301 Ŧ .9406
TR-AP H 18 1.807Ŧ .9650 24 1.727Ŧ .6941 42 1.761 Ŧ .8112
TR-AP Total 36 1.393 .9496 44 1.664 .8481 80 1.542 .8997
CTX W 18 .1659Ŧ .06684 20 .2040Ŧ .12180 38 .1859 Ŧ .10021
CTX H 18 .1111Ŧ .09636 24 .2099Ŧ .11271 42 .1676 Ŧ .11585
CTX Total 36 .1385 .08632 44 .2072 .11558 80 .1763 .10842
Table 3. Results of biochemical determinations of patients.
Ca, Calcium; P, Phosphorus; Al-P, Alkaline phosphatase; BGP, Osteocalcin; Total-AP, Total acid phosphatase; TR-AP, Tartrate-resistant acid 
phosphatase; CTX, Beta-crosslap; W, Women; M, Men; N, Number of cases; SD, Standard deviation; Ŧ,Statistical significance related to nor-
mal population values; *,Statistical significance between groups.
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From the biochemical point of view, the most important 
statistically significant data in our study were those 
indicating the ongoing reduction in carboxylated 
osteocalcin. It means that the main component of the 
osteoid matrix is reduced and so it can be inferred that 
bone remodeling phenomena with new bone formation 
was probably reduced or delayed. Other parameters 
usually affected in these cases – calcium, phosphorous, 
and total alkaline, and bone phosphatase – which are 
linked to osteocalcin, were also found to be displaced 
although they did not decrease to values that could be 
considered pathological or significant from the clinical 
point of view.
Bone resorption parameters – tartrate-resistant acid 
phosphatase, and beta-crosslaps – presented lower 
average values than would be considered normal between 
the general population, a finding that is coherents with 
the known effect of osteocalcin on osteoclast activity 
and differentiation.   
PI data indicated poor plaque control in all cases, show-
ing values of over 67%, with worse oral hygiene between 
men than women. This genres difference agrees with the 
research into populations in the developed world (20). 
Treated patients, for whom bleeding is more frequent 
as a result of anticoagulation treatment, may have more 
fear of the possibility of bleeding during tooth brushing, 
which in turn could lead them to avoid brushing lead-
ing to decreased removal of bacterial plaque, hence the 
higher plaque index seen in Group B than Group A (21), 
like patients reported during periodontal evaluation.
As for gingival bleeding, the results showed an increase 
rate between male patients in relation to the length in 
anticoagulant treatment, which could be related to the 
increased PI and poorer oral hygiene outlined above 
(22). But between the female population, as antico-
agulant treatment time increased (Group B) GI values 
decreased. Although this might appear paradoxical, it 
could be the result of a relation with the osteocalcin and/
or acid phosphatase levels found in the study. Although 
other authors such as Bullón related increased serum 
osteocalcin with deterioration of periodontal status and 
lower treatment response regarding clinical attach-
ment level (CAL) (23,24), the present study population 
showed lower values for biochemical parameters in all 
patients but slight increases in serum levels would bring 
them close to minimum normal values therefore pro-
ducing an improvement in gingival bleeding data.  
With regard to clinical attachment level, no significant 
differences were found between men and women. All 
cases showed moderate increases in CAL (no greater 
than 3.5 mm), with data that agree with epidemio-
logical studies in socioculturally similar populations 
and with epidemiological studies conducted in Spain, 
although these were measured according to the com-
munity periodontal index of treatment needs (CPITN) 
(25-27). Comparing men and women, it was seen that 
for both genres probing depth was slightly greater be-
tween Group B patients than Group A, although differ-
ences were not statistically significant. This could be 
related to deterioration over time, independently of the 
demineralization biochemical markers and connective 
tissue destruction involved in the evolution process of 
periodontal pocket depth (28).
Conclusions
The study population showed a slight to moderate de-
gree of periodontal affectation, the most common dis-
order being gingivitis related to bacterial plaque. Peri-
odontal disorders tended to be more severe in patients 
who had been taking anticoagulants for longer.   
Biochemical results suggest that bone remodeling may 
have an overall decrease with greater affectation of bone 
neoformation phenomena but that bone destruction 
tends to recover and normalize with time. 
As anticoagulant patients suffer chronic conditions and 
so are subject to regular check-ups, we think that there 
are strong reasons for oral hygiene instruction to be in-
cluded in health care services for oral anticoagulation 
patients. This would avoid increasing periodontal lesion 
or complications that require subsequent invasive treat-
ments that could affect anticoagulant management and 
in turn have repercussions for systemic pathologies. 
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